Historical Stock Chart
5 Years : From Jul 2012 to Jul 2017
Teleflex Incorporated (NYSE:TFX) announced today the Arrow FlexTip Plus
Closed Tip, Multi-Port epidural catheter has received 510(k) clearance
from the U.S. Food and Drug Administration (FDA).
The Arrow FlexTip Plus, the market-leading1 Open Tip,
Single-Port epidural catheter, has been proven to significantly reduce
complications commonly associated with epidural catheters, such as vein
cannulations and paresthesia2-3. The Arrow FlexTip Plus
Closed Tip, Multi-Port epidural catheter has been designed using the
same proven technology of the Open Tip, Single-Port catheter, the only
coil-reinforced catheter backed by more than a decade of clinical
evidence. With the addition of the Closed Tip, Multi-Port catheter,
FlexTip Plus now provides the drug dispersion choices clinicians demand.
The coil-reinforced FlexTip Plus catheter material is constructed of
polyurethane, while a majority of spring wound catheters are made of
nylon. This provides a unique balance of softness and strength which
promotes easier insertion, less movement out of the epidural space,
better block quality, and higher satisfaction rates. The Closed Tip,
Multi-Port catheter provides excellent kink resistance and features a
soft, flexible tip with 4 lateral holes.
“Teleflex is adding the FlexTip Plus Closed Tip, Multi-Port to the Arrow
catheter family to continue to support physicians with products that
address the concerns anesthesiologists face on a daily basis,” said Cary
Vance, President, Teleflex Anesthesia and Respiratory. “The FlexTip Plus
Closed Tip, Multi-Port is based on proven technology, helping
anesthesiologists achieve the drug dispersion they prefer with the
quality of care they demand for their patients.”
About Teleflex Incorporated
Teleflex is a leading global provider of specialty medical devices for a
range of procedures in critical care and surgery. Our mission is to
provide solutions that enable healthcare providers to improve outcomes
and enhance patient and provider safety. Headquartered in Limerick, PA,
Teleflex employs approximately 11,500 people worldwide and serves
healthcare providers in more than 130 countries. Additional information
about Teleflex can be obtained from the company's website at teleflex.com.
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
Arrow, FlexTip Plus, and Teleflex are registered trademarks of
Teleflex Incorporated or its affiliates.©2012 Teleflex
Incorporated. Lit. No. 2012-0997.
GHX Market Data, FY 2011
Banwell B.R., Morley-Foster P., Krause B.R. Decreased incidence of
complications in parturients with the Arrow (FlexTip Plus) epidural
catheter. Canadian Journal of Anesthesia. 1998; 45: 370-372.
Junega M., Kargas G.A., Miller D.L. Incidence of epidural vein
cannulation in parturients with three different epidural catheters.
Regional Anesthesia. 1996; 4: S21.